Biontech Se ADR (BNTX)

$102.49 -0.94 (-0.91%)
Market Cap 23.61B
Revenue (ttm) 2.98B
Net Income (ttm) -719.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -24.18%
Debt to Equity Ratio 0.01
Volume 292,088
Avg Vol 905,670
Day's Range N/A - N/A
Shares Out 225.18M
Stochastic %K 24%
Beta 1.54
Analysts Strong Sell
Price Target $136.00

Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical tri...

Industry: Biotechnology
Sector: Healthcare
Phone: 49 6131 9084
Fax: 49 6131 9084
Address:
An der Goldgrube 12, Mainz, Germany
taxplanr
taxplanr Nov. 6 at 7:35 PM
$BNTX $MRNA $PFE is the COVID bioweapon connected to suicide? https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1360338/full
0 · Reply
erevnon
erevnon Nov. 6 at 6:11 PM
UBS maintains BioNTech $BNTX at Neutral and raises the price target from $115 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 5:30 PM
UBS has updated their rating for BioNTech ( $BNTX ) to Neutral with a price target of 117.
0 · Reply
taxplanr
taxplanr Nov. 6 at 4:19 PM
Ignoring safety signals for profits shrinks the market $BNTX $MRNA $PFE https://www.thekingstonreport.com/p/jaws-and-mrna-an-analogy-on-how-injuries?utm_source=post-email-title&publication_id=1103773&post_id=178101007&utm_campaign=email-post-title&isFreemail=false&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Nov. 6 at 3:39 PM
Cause of death not mentioned? $BNTX $MRNA $PFE https://www.cbsnews.com/news/dallas-cowboys-marshawn-kneeland-dead/
1 · Reply
taxplanr
taxplanr Nov. 6 at 9:58 AM
Are Democrats throwing malignantRNA C19 jabs under the bus for political gains? $BNTX $MRNA $PFE https://www.thegatewaypundit.com/2025/11/michigan-governor-gretchen-whitmer-says-she-doesnt-want/
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 6 at 3:30 AM
$BNTX Share Price: $103.50 Contract Selected: Mar 20, 2026 $105 Calls Buy Zone: $6.80 – $8.40 Target Zone: $11.17 – $13.65 Potential Upside: 55% ROI Time to Expiration: 134 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Deylorn_947
Deylorn_947 Nov. 5 at 4:50 PM
$BNTX vax cash, pipeline optionality, buy on deep dips
0 · Reply
taxplanr
taxplanr Nov. 5 at 3:36 PM
50% increase in mortality is easily hidden behind cancer and chemo drugs that do the same $BNTX $MRNA $PFE https://kirschsubstack.com/p/time-series-analysis-of-the-czech?utm_source=post-email-title&publication_id=548354&post_id=177943563&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
1 · Reply
SmallCapAlert
SmallCapAlert Nov. 5 at 3:34 PM
$LTELF Watchlist German Stocks: $LTELF cheapest german company in defense AI Defense solutions https://www.lstelcom.com/en/applications-use-cases/artificial-intelligence-solutions/ Revenue is much higher than the small marketcap. Why is the marketcap so low? Marketcap: $24 million FreeFloat: 1.6 million $BNTX Marketcap: $25 billion $BAYRY Marketpcap: $28 billion $DB Marketcap: $80 billion $RNMBY
0 · Reply
Latest News on BNTX
BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold

Nov 3, 2025, 1:44 PM EST - 3 days ago

BioNTech Q3 Earnings: Plenty Of Cash And Pipeline Potential, But Still A Hold

BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 12:46 PM EST - 3 days ago

BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

Nov 3, 2025, 10:29 AM EST - 3 days ago

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

BMY

BioNTech lifts 2025 revenue guidance on BMS partnership payment

Nov 3, 2025, 6:47 AM EST - 3 days ago

BioNTech lifts 2025 revenue guidance on BMS partnership payment

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

Nov 3, 2025, 6:45 AM EST - 3 days ago

BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update

BioNTech to Host Innovation Series R&D Day on November 11, 2025

Oct 28, 2025, 7:45 AM EDT - 9 days ago

BioNTech to Host Innovation Series R&D Day on November 11, 2025

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

Oct 27, 2025, 7:45 AM EDT - 10 days ago

BioNTech to Report Third Quarter 2025 Financial Results and Corporate Update on November 3, 2025

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Oct 22, 2025, 6:45 AM EDT - 15 days ago

BioNTech Commences Public Exchange Offer for All Outstanding Shares of CureVac N.V.

Moderna Vs BioNTech: Who's Winning The Post-COVID Race

Oct 18, 2025, 9:30 AM EDT - 19 days ago

Moderna Vs BioNTech: Who's Winning The Post-COVID Race

MRNA

BioNTech SE, InstaDeep Ltd - Special Call

Oct 1, 2025, 6:52 PM EDT - 5 weeks ago

BioNTech SE, InstaDeep Ltd - Special Call

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

Sep 23, 2025, 6:45 AM EDT - 6 weeks ago

BioNTech to Host Second AI Day as an Edition of Its Innovation Series on October 1, 2025

Mizuho's Jared Holz: There's not much value left in vaccine stocks

Sep 19, 2025, 11:40 AM EDT - 6 weeks ago

Mizuho's Jared Holz: There's not much value left in vaccine stocks

MRNA NVAX PFE

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

Sep 12, 2025, 1:37 PM EDT - 7 weeks ago

COVID vaccine makers' shares fall as Trump officials to link shots to child deaths, report says

JNJ KVUE MRNA PFE

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

Sep 8, 2025, 2:01 PM EDT - 2 months ago

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

BMY

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

Sep 8, 2025, 11:05 AM EDT - 2 months ago

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

BMY

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Sep 8, 2025, 11:00 AM EDT - 2 months ago

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Pfizer, partner BioNTech say updated COVID shot shows better immune response

Sep 8, 2025, 7:02 AM EDT - 2 months ago

Pfizer, partner BioNTech say updated COVID shot shows better immune response

PFE

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

Sep 8, 2025, 6:45 AM EDT - 2 months ago

Pfizer and BioNTech Announce Topline Data Demonstrating Robust Immune Response With Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 Formula

PFE

BioNTech, Duality score initial trial win with breast cancer precision drug

Sep 5, 2025, 5:13 AM EDT - 2 months ago

BioNTech, Duality score initial trial win with breast cancer precision drug

mRNA Biotechs - Long-Term Value Risks Abound

Aug 28, 2025, 6:20 AM EDT - 2 months ago

mRNA Biotechs - Long-Term Value Risks Abound

ALNY DHR GRAL ILMN IONS MRNA RGEN

Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

Aug 27, 2025, 12:50 PM EDT - 2 months ago

Pfizer and BioNTech's COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

PFE

CureVac settles patent dispute litigation with Pfizer and BioNTech

Aug 7, 2025, 9:00 PM EDT - 3 months ago

CureVac settles patent dispute litigation with Pfizer and BioNTech

CVAC PFE

These Analysts Revise Their Forecasts On BioNTech After Q2 Results

Aug 5, 2025, 1:36 PM EDT - 3 months ago

These Analysts Revise Their Forecasts On BioNTech After Q2 Results

BioNTech SE (BNTX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 1:56 PM EDT - 3 months ago

BioNTech SE (BNTX) Q2 2025 Earnings Call Transcript

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

Aug 4, 2025, 10:32 AM EDT - 3 months ago

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

BioNTech Stock Rises as Drug Maker Beats Earnings Expectations.

Aug 4, 2025, 7:01 AM EDT - 3 months ago

BioNTech Stock Rises as Drug Maker Beats Earnings Expectations.

BioNTech's Q2 revenues double on higher COVID vaccine sales

Aug 4, 2025, 6:52 AM EDT - 3 months ago

BioNTech's Q2 revenues double on higher COVID vaccine sales

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

Aug 4, 2025, 6:45 AM EDT - 3 months ago

BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update

Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent

Aug 1, 2025, 4:51 PM EDT - 3 months ago

Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent

MRNA PFE

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 3 months ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 3 months ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win

Aug 1, 2025, 5:59 AM EDT - 3 months ago

Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win

MRNA PFE

Pandemic darlings Moderna, BioNTech are now on two different paths

Jul 31, 2025, 7:00 AM EDT - 3 months ago

Pandemic darlings Moderna, BioNTech are now on two different paths

MRNA

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

Jul 25, 2025, 2:30 AM EDT - 3 months ago

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union

Jul 25, 2025, 2:30 AM EDT - 3 months ago

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union

PFE

8MM Exanthema Market Report 2025-2034 | Rising Viral Infections and Diagnostic Innovations Across Major Markets Fueling Growth

Jul 23, 2025, 4:11 AM EDT - 3 months ago

8MM Exanthema Market Report 2025-2034 | Rising Viral Infections and Diagnostic Innovations Across Major Markets Fueling Growth

PFE

BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025

Jul 21, 2025, 6:45 AM EDT - 3 months ago

BioNTech to Report Second Quarter 2025 Financial Results and Corporate Update on August 4, 2025

BioNTech Announces Ryan Richardson to Step Down from the Management Board

Jul 17, 2025, 8:30 AM EDT - 4 months ago

BioNTech Announces Ryan Richardson to Step Down from the Management Board

Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win

Jul 10, 2025, 7:18 AM EDT - 4 months ago

Pfizer, BioNTech ask UK court to overturn Moderna's COVID vaccine patent win

MRNA PFE

5 Stocks To Ride The German Market Rally

Jun 16, 2025, 3:06 PM EDT - 5 months ago

5 Stocks To Ride The German Market Rally

FMS SAP

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

Jun 12, 2025, 11:07 AM EDT - 5 months ago

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

CVAC

BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.

Jun 12, 2025, 7:11 AM EDT - 5 months ago

BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.

CVAC

BioNTech to acquire CureVac in $1.25 billion all-stock deal

Jun 12, 2025, 7:03 AM EDT - 5 months ago

BioNTech to acquire CureVac in $1.25 billion all-stock deal

CVAC

BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer

Jun 12, 2025, 6:45 AM EDT - 5 months ago

BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer

RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts say

Jun 10, 2025, 11:50 AM EDT - 5 months ago

RFK Jr.'s firing of CDC vaccine advisors 'circumvents science' and could threaten public health, experts say

MRK MRNA PFE

Vaccine actions and policy positions under US Health Secretary Kennedy

Jun 10, 2025, 10:45 AM EDT - 5 months ago

Vaccine actions and policy positions under US Health Secretary Kennedy

MRNA NVAX PFE

Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up

Jun 10, 2025, 9:30 AM EDT - 5 months ago

Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up

MRNA NVAX PFE

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.

Jun 10, 2025, 8:18 AM EDT - 5 months ago

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors.

MRNA NVAX PFE SNY

Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment

Jun 6, 2025, 7:00 AM EDT - 5 months ago

Bristol-Myers And BioNTech Deal: Good For Both Parties, But One Is The Better Investment

BMY

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

Jun 3, 2025, 3:34 PM EDT - 5 months ago

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

AZN GILD PFE AMGN BMY MRK

taxplanr
taxplanr Nov. 6 at 7:35 PM
$BNTX $MRNA $PFE is the COVID bioweapon connected to suicide? https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1360338/full
0 · Reply
erevnon
erevnon Nov. 6 at 6:11 PM
UBS maintains BioNTech $BNTX at Neutral and raises the price target from $115 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
JarvisFlow
JarvisFlow Nov. 6 at 5:30 PM
UBS has updated their rating for BioNTech ( $BNTX ) to Neutral with a price target of 117.
0 · Reply
taxplanr
taxplanr Nov. 6 at 4:19 PM
Ignoring safety signals for profits shrinks the market $BNTX $MRNA $PFE https://www.thekingstonreport.com/p/jaws-and-mrna-an-analogy-on-how-injuries?utm_source=post-email-title&publication_id=1103773&post_id=178101007&utm_campaign=email-post-title&isFreemail=false&r=18m8lm&triedRedirect=true&utm_medium=email
0 · Reply
taxplanr
taxplanr Nov. 6 at 3:39 PM
Cause of death not mentioned? $BNTX $MRNA $PFE https://www.cbsnews.com/news/dallas-cowboys-marshawn-kneeland-dead/
1 · Reply
taxplanr
taxplanr Nov. 6 at 9:58 AM
Are Democrats throwing malignantRNA C19 jabs under the bus for political gains? $BNTX $MRNA $PFE https://www.thegatewaypundit.com/2025/11/michigan-governor-gretchen-whitmer-says-she-doesnt-want/
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 6 at 3:30 AM
$BNTX Share Price: $103.50 Contract Selected: Mar 20, 2026 $105 Calls Buy Zone: $6.80 – $8.40 Target Zone: $11.17 – $13.65 Potential Upside: 55% ROI Time to Expiration: 134 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Deylorn_947
Deylorn_947 Nov. 5 at 4:50 PM
$BNTX vax cash, pipeline optionality, buy on deep dips
0 · Reply
taxplanr
taxplanr Nov. 5 at 3:36 PM
50% increase in mortality is easily hidden behind cancer and chemo drugs that do the same $BNTX $MRNA $PFE https://kirschsubstack.com/p/time-series-analysis-of-the-czech?utm_source=post-email-title&publication_id=548354&post_id=177943563&utm_campaign=email-post-title&isFreemail=true&r=18m8lm&triedRedirect=true&utm_medium=email
1 · Reply
SmallCapAlert
SmallCapAlert Nov. 5 at 3:34 PM
$LTELF Watchlist German Stocks: $LTELF cheapest german company in defense AI Defense solutions https://www.lstelcom.com/en/applications-use-cases/artificial-intelligence-solutions/ Revenue is much higher than the small marketcap. Why is the marketcap so low? Marketcap: $24 million FreeFloat: 1.6 million $BNTX Marketcap: $25 billion $BAYRY Marketpcap: $28 billion $DB Marketcap: $80 billion $RNMBY
0 · Reply
jogabonito84
jogabonito84 Nov. 5 at 8:29 AM
$IBRX $MRK $BNTX $TSLA $NVDA Revenue up +467% year-to-date ($74.7 million) — exceptional growth for a biotech firm. ANKTIVA® (their bladder-cancer treatment) is performing far above expectations, with broad adoption among urologists and strong reorder trends. Q3 2025 revenue up +434% year-over-year, showing consistent acceleration, not a one-time spike. Cash position of $257 million gives ImmunityBio solid liquidity to fund operations and clinical programs without immediate need for new financing. Net loss narrowed to $289 million (from $354 million YoY), signaling improving cost control and early operating leverage.
0 · Reply
Lambo2
Lambo2 Nov. 4 at 11:32 PM
$BNTX
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 4 at 2:04 PM
$PRDL $AON $AR $BNTX $BTDR 🔥 Cycle Trading Signal plugged into 🔥 AI 🔥 lists 🔥 Nothing 💫 More 💫 Accurate 🔥
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 3 at 10:09 PM
$BNTX $BTDR $BTU $CACC list 11/2025 for the next 21 trading days ✨️ hitting targets and over in the first day CYCLE TRADING SIGNAL PLUGGED INTO AI 🔥 LISTS 🔥 NOTHING ELSE IS MORE ACCURATE
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 3 at 8:15 PM
$BNTX $BTDR $BTU $CACC 🔥 CYCLE TRADING SIGNAL PLUGGED INTO AI 🔥 LIST 🔥 Day 1 List 11/2025
0 · Reply
taxplanr
taxplanr Nov. 3 at 3:35 PM
When it comes to Cancer treatment and when the public is shown the Science do you think they will choose PEMF or chemo and malignantRNA combos? $BNTX $MRNA $PFE $BMY
0 · Reply
taxplanr
taxplanr Nov. 3 at 3:03 PM
malignantRNA makers hooking up with chemo makers to combine Effectiveness $BNTX $MRNA $PFE what could go wrong? https://www.wakingtimes.com/97-percent-time-chemotherapy-work-continues-used-one-reason/
0 · Reply
taxplanr
taxplanr Nov. 3 at 2:51 PM
$BNTX Lower sales volumes for their only gene therapy on the market No mention of any phase 3 trials No mention of how they can support $CVAC losses and trials
0 · Reply
tkstockpicker
tkstockpicker Nov. 3 at 1:30 PM
$BNTX LFG
0 · Reply
topstockalerts
topstockalerts Nov. 3 at 12:40 PM
BioNTech lifted its 2025 revenue forecast after receiving upfront payments from its new cancer immunotherapy partnership with Bristol Myers Squibb, a deal designed to challenge Merck’s top-selling Keytruda. The German biotech now expects full-year revenue between €2.6 billion and €2.8 billion, compared with a prior range of €1.7 billion to €2.2 billion. Under the agreement, Bristol Myers could pay up to $11.1 billion over time, contingent on achieving certain milestones. BioNTech — known for its COVID-19 vaccine collaboration with Pfizer — reported a 22% year-over-year increase in third-quarter revenue to €1.52 billion. The company also said it expanded the clinical trial program for pumitamig, the cancer therapy at the center of the alliance, during the third quarter, with additional studies expected to begin in 2026. $BNTX $BMY $MRK $PFE
0 · Reply
DonCorleone77
DonCorleone77 Nov. 3 at 11:52 AM
$BNTX BioNTech Q3 EPS EUR (0.12) vs. EUR (0.81) last year -- Q3 revenue EUR 1.52B vs. EUR 1.24B last year. -- Raises FY25 revenue view to EUR 2.6B-EUR 2.8B from EUR 1.7B-EUR 2.2B -- Cuts FY25 CapEx view to EUR 200M-EUR 250M from EUR 250M-EUR 350M.
0 · Reply
__SquuezedChronometer_
__SquuezedChronometer_ Nov. 2 at 11:35 AM
Next major retail squeeze candidate right here $BEPC $TCOM $BNTX $ACMR 5
0 · Reply